Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer

被引：0
|
作者：
Ken-ichi Fujita
Yuichi Ando
Fumio Nagashima
Wataru Yamamoto
Hisashi Eodo
Kazuhiro Araki
Keiji Kodama
Toshimichi Miya
Masaru Narabayashi
Yasutsuna Sasaki
机构：
[1] Saitama Medical University,Department of Clinical Oncology
[2] Saitama Medical University,Project Research Laboratory, Research Center for Genomic Medicine, Saitama Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Irinotecan; SN-38; Polymorphism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：515 / 522
页数：7
相关论文
共 50 条
  • [31] Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
    Amandito, Radhian
    Rohsiswatmo, Rinawati
    Carolina, Erica
    Maulida, Rizka
    Kresnawati, Windhi
    Malik, Amarila
    FRONTIERS IN PEDIATRICS, 2019, 7
  • [32] Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver
    Ramirez, J.
    Mirkov, S.
    Zhang, W.
    Chen, P.
    Das, S.
    Liu, W.
    Ratain, M. J.
    Innocenti, F.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (02): : 152 - 161
  • [33] Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver
    J Ramírez
    S Mirkov
    W Zhang
    P Chen
    S Das
    W Liu
    M J Ratain
    F Innocenti
    The Pharmacogenomics Journal, 2008, 8 : 152 - 161
  • [34] UGT1A1 and UGT1A9 variants affect thyroxine glucuronidation in human livers.
    Graber, AY
    Innocenti, F
    Ramirez, J
    Chen, PX
    Das, S
    Ratain, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P73 - P73
  • [35] UGT1A1*6 AND UGT1A1*27 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE NEUTROPENIA IN JAPANESE PATIENTS WITH NSCLC
    Doi, S.
    Nakamura, Y.
    Fukuda, M.
    Takatani, H.
    Fukuda, M.
    Kinoshita, A.
    Soda, H.
    Oka, M.
    Tsukamoto, K.
    Kohno, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 165 - 165
  • [36] The UGT1A9 intronic 1399 polymorphism is not associated with UGT1A9 activity or mRNA expression.
    Ramirez, J.
    Liu, W.
    Desai, A. A.
    Mirkov, S.
    Chen, P.
    Das, S.
    Innocenti, F.
    Ratain, M. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S87 - S87
  • [37] UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro
    Li, Ji
    Xu, Zhangyao
    Gu, Jifeng
    MOLECULES, 2022, 27 (13):
  • [38] UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
    Ando, Y
    Saka, H
    Asai, G
    Sugiura, S
    Shimokata, K
    Kamataki, T
    ANNALS OF ONCOLOGY, 1998, 9 (08) : 845 - 847
  • [39] Commentary: Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
    Heydari, Mohammad Reza
    Fardaei, Majid
    FRONTIERS IN PEDIATRICS, 2020, 7
  • [40] Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9
    Kishi, Naoki
    Takasuka, Akane
    Kokawa, Yuki
    Isobe, Takashi
    Taguchi, Maho
    Shigeyama, Masato
    Murata, Mikio
    Suno, Manabu
    Hanioka, Nobumitsu
    XENOBIOTICA, 2016, 46 (04) : 289 - 295
12345